Leukemia Adapted Protocol

Inclusion Criteria: 1. Age Patients must be \<18 years of age at time of study enrollment. 2. Diagnosis Patients must be diagnosed with de novo AML according to 2022 WHO 5th Edition classification with or without extramedullary disease. Patients must have one of the following: * Bone marrow myeloblasts ≥20%. In cases of dry taps due to fibrosis, myeloblast percentage can be estimated from a bone marrow biopsy core specimen. Due to unavailable molecular/cytogenetic diagnostics in Malawi, patients with \<20% bone marrow myeloblasts can be included in the study at the discretion of the treating oncologist with rationale documented. * In cases where a bone marrow evaluation is not safe/feasible, a peripheral blood sample may be used with a documented absolute myeloblast percentage of ≥1000/μL calculated based on a total white blood cell count and percentage circulating blasts. 3. Therapy Patients must begin treatment according to the 2023 KCH AML therapy CPG. Exclusion Criteria: 1. Patients with any of the following conditions or criteria will be excluded from the study: * Juvenile myelomonocytic leukemia * Transient myeloproliferative disorder * Acute promyelocytic leukemia * Mixed phenotype acute leukemia * Trisomy 21 * Current pregnancy * Previous or concurrent malignancy * Isolated myeloid sarcoma 2. Patients previously treated with antineoplastic therapy with the following exceptions: * Hydroxyurea * Corticosteroids * Intrathecal chemotherapy at diagnosis